tiprankstipranks
Rapid Nutrition PLC (FR:ALRPD)
:ALRPD
Want to see FR:ALRPD full AI Analyst Report?

Rapid Nutrition (ALRPD) AI Stock Analysis

6 Followers

Top Page

FR:ALRPD

Rapid Nutrition

(ALRPD)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - Gpt-5.6Sol)
Rating:41Neutral
Price Target:
€2.50
▼(-25.60% Downside)
Action:Reiterated
Date:09/09/26
The score is driven primarily by weak financial performance—steep revenue contraction, extreme losses, and persistent negative free cash flow—partly offset by very low reported leverage. Technicals remain pressured with negative MACD and the price below key longer-term moving averages, while valuation is constrained by a negative P/E (loss-making) and no stated dividend yield.
Positive Factors
Low leverage
Very low reported leverage gives Rapid Nutrition a stronger capital structure than in 2022–2023, when debt-to-equity was highly elevated. This reduces debt-service pressure and preserves financial flexibility, although the benefit is tempered by continuing losses and negative returns.
Negative Factors
Severe revenue contraction
A revenue collapse of this magnitude indicates major deterioration in demand, distribution, or business scale and weakens the platform available to absorb fixed costs. Continued contraction would make a return to sustainable profitability harder and could further erode competitive position.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low reported leverage gives Rapid Nutrition a stronger capital structure than in 2022–2023, when debt-to-equity was highly elevated. This reduces debt-service pressure and preserves financial flexibility, although the benefit is tempered by continuing losses and negative returns.
Read all positive factors

Rapid Nutrition (ALRPD) vs. iShares MSCI France ETF (EWQ)

Rapid Nutrition Business Overview & Revenue Model

Company Description
Rapid Nutrition PLC is a natural healthcare enterprise that researches, develops, and manufactures a diverse portfolio of science-backed health and wellness products. Its market presence extends across the United Kingdom, Australia, Asia, the Unit...

Rapid Nutrition Financial Statement Overview

Summary
Financial health is highly stressed: revenue fell sharply in 2025 (~-72% YoY), profitability is deeply negative (net margin ~-1,596%), and cash generation remains materially negative (FCF about -€3.1M in 2025). The main offset is a much improved capital structure with very low reported leverage (debt-to-equity ~0.01), but negative ROE (~-36%) and ongoing cash burn keep overall financial risk elevated.
Income Statement
12
Very Negative
Balance Sheet
36
Negative
Cash Flow
10
Very Negative
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue194.33K917.04K1.66M2.96M2.79M
Gross Profit52.93K482.09K817.59K2.08M2.04M
EBITDA-2.61M-1.52M-1.94M-8.64M593.71K
Net Income-3.10M-2.90M-2.13M-9.97M238.07K
Balance Sheet
Total Assets9.07M955.55K918.27K588.30K2.62M
Cash, Cash Equivalents and Short-Term Investments8.55M95.81K488.10K236.12K77.51K
Total Debt77.87K88.08K194.87K356.03K2.12M
Total Liabilities549.66K574.14K877.66K480.36K3.53M
Stockholders Equity8.52M381.41K40.61K107.94K-909.79K
Cash Flow
Free Cash Flow-3.12M-3.00M-1.55M-2.36M-146.36K
Operating Cash Flow-3.12M-3.00M-1.55M-2.36M-146.36K
Investing Cash Flow-1.54K0.000.000.0011.16K
Financing Cash Flow11.59M2.61M1.80M1.46M-117.24K

Rapid Nutrition Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
€458.99M13.988.57%5.19%2.78%187.96%
56
Neutral
€91.94M32.456.80%15.43%4.46%133.27%
56
Neutral
€855.82M10.994.66%2.30%-1.52%-16.10%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
44
Neutral
€166.37M5.6533.68%0.58%-11.89%1623.56%
41
Neutral
€17.92M-1.35-62.22%-41.21%73.08%
38
Underperform
€268.18M5.443.60%3.00%-3.63%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:ALRPD
Rapid Nutrition
2.81
-1.54
-35.40%
FR:BLC
Bastide le Confort Medical
22.60
-3.10
-12.06%
FR:BOI
Boiron SA
26.00
2.80
12.05%
FR:BON
Bonduelle
8.33
1.09
15.02%
FR:ALFLE
Fleury Michon
21.90
-0.32
-1.42%
FR:SAVE
Savencia
61.00
0.38
0.62%

Rapid Nutrition Corporate Events

Rapid Nutrition posts surging H1 revenue and expands via HealthShop+ acquisition
Sep 8, 2026
Rapid Nutrition has reported unaudited interim results for the six months to 30 June 2026, showing a 227.5% increase in revenue and a 122.3% rise in gross profit versus the prior year period. The performance was driven largely by its established b...
Rapid Nutrition triples H1 revenue and expands with HealthShop+ acquisition
Sep 8, 2026
Rapid Nutrition reported a 227.5% year-on-year increase in first-half revenue and a 122.3% rise in gross margin, driven primarily by its historic brands as it executes a strategic refocus begun in 2025. The company also continued to invest heavily...
Rapid Nutrition Wins Global Media Spotlight for AI-Driven HealthTech Strategy
Aug 4, 2026
Rapid Nutrition is positioning itself at the nexus of artificial intelligence, personalized wellness and digital health, combining proprietary consumer insights, evidence-based nutrition and vertically integrated operations in a single HealthTech ...
Rapid Nutrition launches data-driven Premium Nutrition Pantry to boost owned-brand growth
Jul 28, 2026
Rapid Nutrition has launched a new Premium Nutrition Pantry range across its HealthShop+ wellness hub network and online channels, initially offering up to 100 premium wholefood products made from sustainably sourced, minimally processed ingredien...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 09, 2026